We previously showed that Bcl-x L and Mcl-1 cooperatively protect platinum-resistant ovarian cancer cells from apoptosis. Here we assessed the anticancer potential of combining ABT-737-induced inhibition of Bcl-x L with Mcl-1 inhibition via PI3K/Akt/mTOR pathway disruption using NVP-BEZ235. NVP-BEZ235 inhibited cell proliferation without inducing apoptosis. It strongly repressed Mcl-1 expression and induced Puma expression in both cell lines tested while differentially modulating Bim between the two. Interestingly, NVP-BEZ235 efficiently sensitized ovarian carcinoma cells to ABT-737, provided that Bim expression was induced. Moreover, inhibiting the ERK1/2 pathway restored Bim expression and sensitized low Bim-expressing cancer cells to the BEZ235/ABT-737 treatment.
Introduction
Ovarian cancers represent the leading cause of death from gynaecologic malignancies and the fifth most frequent cause of cancer death of women in the United States [1] . The majority of patients present with advanced disease and their treatment consists of debulking surgery followed by platinum/taxane-based chemotherapy [2] . Despite a high response rate to this first-line therapy, most patients relapse and develop chemoresistance. Therefore, the 5-year survival rate of patients with advanced ovarian cancer is very poor, currently below 30%. The identification of novel therapeutic strategies thus represents an important goal for the clinical management of such cancers.
Upregulation of anti-apoptotic members of the Bcl-2 family and subsequent alteration of the balance between pro-and anti-apoptotic members are frequently found in cancer cells. These anti-apoptotic proteins counteract the death signals induced by oncogenic stress in cancer cells by sequestrating the pro-apoptotic members of the Bcl-2 family [3] . Cancer cells are thus qualified as ''primed for death'' and may be addicted to Bcl-2 family anti-apoptotic proteins for their survival [3] . Exploiting this addiction appears as an attractive strategy for anticancer therapy. In line with this notion, we previously showed that concomitant inhibition of Bcl-x L and Mcl-1 was sufficient to induce massive apoptosis in resistant ovarian carcinoma cells, even in the absence of chemotherapy [4] [5] [6] . Bcl-x L and Mcl-1 proteins thus cooperate to protect resistant ovarian cancer cells from apoptosis and together constitute a strong molecular ''bolt'' the elimination of which is sufficient to allow apoptotic cell death.
One available pharmacological approach to inhibit anti-apoptotic Bcl-2 family members and thereby trigger apoptosis consists in disrupting their interactions with their pro-apoptotic partners using BH3-mimetic molecules [7] . ABT-737 is one of the most potent and specific BH3-mimetic compounds [8] available form, ABT-263 (Navitoclax), is currently undergoing phase I and II clinical evaluation in various tumour types [9, 10] . ABT-737 binds with high affinity to Bcl-2, Bcl-x L and Bcl-w and antagonizes their anti-apoptotic function [8] . It has been shown to induce apoptosis in several cellular models [8, [11] [12] [13] and to sensitize cancer cells to chemotherapeutic agents such as platinum compounds [5, 14] . However, ABT-737 is unable to inhibit the activity of Mcl-1, the expression of which hinders ABT-737-induced apoptosis in various cancer types [12, [15] [16] [17] [18] including ovarian cancers [5] . Moreover, ABT-737 is able to stabilize Mcl-1 in various contexts [5, 18, 19] . Therefore, Mcl-1 inhibition represents an important obstacle to overcome before the successful implementation of Bcl-x L -targeting therapies, including the use of BH3-mimetic molecules.
Inhibiting Mcl-1 activity can be achieved either by inhibiting Mcl-1 expression or by promoting the expression/activation of its endogenous inhibitors, the pro-apoptotic BH3-only proteins. Indeed, tBid, Bim, Puma and Noxa BH3-only proteins compete against the pro-apoptotic proteins Bak and Bax for their binding to Mcl-1 [20] . Pharmacological inhibition of signaling pathways that promote Mcl-1 and inhibit BH3-only proteins could therefore be efficient to sensitize ovarian cancer cells to ABT-737. In this context, the PI3K/Akt/mTOR pathway appears as an attractive target. First, it promotes Mcl-1 expression at different levels: (i) transcriptional, via the activation of CREB transcription factor [21] ; (ii) translational, via the activation of mTORC1 and subsequent phosphorylation of 4E-BP1 [22, 23] ; and (iii) post-translational, through decreased proteasomal degradation due to repression of GSK3-induced phosphorylation [24] . Moreover, the PI3K/Akt/mTOR pathway can also modulate Mcl-1 activity by regulating Bim expression and phosphorylation [25, 26] and Puma expression [27] . Second, this pathway has been demonstrated to interact coordinately with Bcl-2 and/or Bcl-x L to promote survival of cancer cells [28, 29] . Finally, the PI3K/Akt/mTOR pathway has been reported to be one of the most deregulated signaling pathways in many tumours including ovarian tumours [30] .
Among the PI3K/Akt/mTOR inhibitors, PI3K/mTOR dual inhibitors are extremely useful to target in full the pathway both upstream and downstream, thus avoiding undesirable feedback regulations that are described to occur with rapalogs [31] . NVP-BEZ235 (hereafter referred to as BEZ235) is an imidazo [4,5-c] quinoline derivative that inhibits both pan-class I PI3K and mTOR kinase (in mTORC1 and mTORC2 complexes) by binding reversibly and competitively to the ATP-binding cleft of these enzymes [32] . It shows antiproliferative and antitumor activity in vitro and in vivo in a great variety of cancer types [32] [33] [34] [35] [36] , and is currently being tested in phase I and II clinical trials. Moreover, a few studies have provided evidence for the efficacy of BEZ235 in ovarian cancer cells, showing it to efficiently decrease cell proliferation in vitro and tumour growth in vivo [37, 38] , reduce cell migration in vitro [38] and display synergistic effect when combined with platinum derivatives [37, 38] or taxanes [37] .
However, the impact of PI3K/Akt/mTOR pathway modulation by BEZ235 on the expression of Mcl-1 and its partners has never been explored in ovarian cancers. We thereby studied the effect of BEZ235 on the expression of both Mcl-1 and BH3-only proteins Noxa, Puma and Bim in chemoresistant IGROV1-R10 and SKOV3 cell lines and its ability to sensitize these cells to Bcl-x L -targeting strategies.
Materials and methods

Cell culture and treatment
The human ovarian carcinoma cell lines SKOV3, IGROV1-R10 and IGROV1 were used. SKOV3 and IGROV1-R10 cells were platinum-resistant, whereas IGROV1 cells were platinum-sensitive. SKOV3 was obtained from American Type Culture Collection (Manassas, USA) and IGROV1-R10 was established as previously described [39] from the IGROV1 cell line, kindly provided by Dr. Jean Bénard (Institut Gustave Roussy, Villejuif, France). All of the cell lines were grown in RPMI Medium 1640 + Glutamax™ (Gibco, Paisley, UK) supplemented with 10% Foetal Bovine Serum (Gibco) and 33 mM sodium bicarbonate (Gibco) and were maintained in a 5% CO 2 humidified atmosphere at 37°C.
The PI3K/mTOR dual inhibitors BEZ235 and NVP-BGT226 (hereafter referred to as BGT226), the MEK inhibitor CI-1040 and ABT-737 were purchased from Selleck Chemicals (Munich, Germany). Stock solutions were prepared in DMSO at 5 mM, 5 mM, 25 mM and 20 mM respectively and stored according to the manufacturer's instructions. A total of 5 x 10 5 cells were plated in 25 cm 2 flasks and treated 24 h later, when cells had reached their exponential growth phase.
siRNA synthesis and transfection
All siRNAs used in this study were chemically synthesised by Eurogentec (Liege, Belgium) and were received as annealed oligonucleotides. Sequences were as follows: Bcl-x L siRNA antisense (denoted siBcl-x L , targeting specifically the Bcl-x L mRNA but not the Bcl-x S mRNA), 5 
Proliferation analysis
Cell number and viability were estimated at various times after the beginning of treatment by a semi-automated image-based cell analyzer (Cedex XS Analyzer, Roche Applied Science, Meylan, France) using the Trypan blue exclusion method. 
RNA extraction and real-time quantitative reverse transcription PCR (qRT-PCR)
Extraction of proteins and western-blot analysis
Proteins were extracted as follows: cells were rinsed with ice-cold PBS, lysed in 50 mM Tris-HCl (pH 8), 150 mM NaCl, 1% Nonidet P-40, 5 mM EDTA, 10 mM NaF, 4 mM PMSF, 2 mM aprotinin, 10 mM NaPPi, 1 mM Na3VO4 and a complete mini mixture of protease inhibitors (Roche Applied Science) and incubated on ice for 30 min. Lysates were collected after centrifugation (13,000 g, 10 min, 4°C) and protein concentrations were determined using the Bradford assay (Bio-Rad, Hercules, USA). Equal amounts of proteins (30 lg) were separated by SDS-PAGE on a 4-15% gradient polyacrylamide Mini-PROTEAN Ò TGX™ precast gel (Bio-Rad) and transferred to PVDF membranes (Bio-Rad). Membranes were blocked for 2 h at RT with 5% (w/v) non-fat dry milk in TBS with 0.05% (v/v) Tween20 (T-TBS). Membranes were then incubated overnight at 4°C with the primary antibodies. P-Akt (Ser473), P-Akt (Thr308), Akt, P-4E-BP1 (Thr70), 4E-BP1, P-p70S6 K (Thr389), p70S6 K, P-ERK1/2 (Thr202/Tyr204), ERK1/2, caspase 3, PARP, Bcl- Immunoprecipitates, supernatant (18 lg) and total cell extracts (18 lg) were separated by SDS-PAGE and the expression of Bim and Bcl-x L proteins was analyzed as described in the previous section.
Nuclear staining with 4 0 ,6-diamidino-2-phenylindole (DAPI)
Both detached and adherent cells were pooled, collected on a polylysine-coated glass slide by cytospin centrifugation and fixed with a solution of ethanol/chloroform/acetic acid (6:3:1). The preparations were then incubated with 1 lg/ml DAPI (Boehringer Mannheim, Germany) in water at RT. After 30 min, they were extensively washed in ultra pure water and mounted in Mowiol (Calbiochem) under a coverslip.
Analysis of DNA cellular content by flow cytometry
Both detached and adherent cells were pooled, washed with 1X PBS and fixed with 70% ethanol. Cells were then centrifuged at 4000 rpm for 5 min and incubated for 30 min at 37°C in PBS to allow the release of low-molecular weight DNA, characteristic of apoptotic cells. Cell pellets were stained with propidium iodide (PI) using the DNA Prep Coulter Reagent Kit (Beckman-Coulter, Villepinte, France). Samples were thereafter analyzed using a Gallios flow cytometer (Beckman-Coulter) and cell cycle distribution was determined using Kaluza acquisition software (Beckman-Coulter).
Real-time cell analysis (xCELLigence)
Treatment-mediated cytotoxicity was monitored with the Real-Time Cell Analyzer multi-plate (RTCA MP) Instrument, using the xCELLigence System (Roche Applied Science, Mannheim, Germany). This system monitors cellular events in real time by measuring electrical impedance across interdigitated micro-electrodes integrated on the bottom of tissue culture E-plates (96-well View, Roche). The increase in the number and size of cells attached to the electrode sensors leads to increased impedance, based on which the Cell Index values are derived and displayed in the plot. This index thus reflects changes in cell viability as described by Ke et al. [40] . Briefly, 7 x 10 3 IGROV1-R10 cells/per well were plated in an E-Plate View 96
and placed onto the RTCA MP located inside a tissue culture incubator. Cells were left to grow for 24 h before treatment and impedance was continuously measured until the end of the treatment. Standard deviations of well replicates were analyzed with the RTCA Software.
Statistical analysis
Relative values were compared to the value of the control condition (100 or 1) by a one-sample Student's t test. Groups for Real-Time Cell Analysis were compared using a two-sample Student's t test. Bilateral alpha risk was set to 0.05 for each statistical test.
Results
BEZ235 inhibits PI3K/Akt/mTOR pathway activation in platinumresistant SKOV3 and IGROV1-R10 ovarian cancer cell lines
We first analyzed the activation status of the PI3K/Akt/mTOR pathway in SKOV3 and IGROV1-R10 cisplatin-resistant ovarian carcinoma cell lines. This was achieved by studying the phosphorylation of Akt residues governed by PI3K-initiated events (Thr308) or by mTORC2 (Ser473) and the phosphorylation of mTORC1 targets p70S6K (Thr389) and 4E-BP1 (Thr70). Our results showed that both cell lines displayed activation of Akt, p70S6K and 4E-BP1 (Fig. 1A ) and that these activations were stronger in the IGROV1-R10 cell line than in the SKOV3.
We then investigated the impact of a range of concentrations of BEZ235 on PI3K/Akt/mTOR pathway activation in our cell lines. BEZ235 at concentrations of 250 nM or higher efficiently inhibited the phosphorylation of Akt on Ser473 and Thr308 in both cell lines (Fig. 1B) . Furthermore, a strong inhibition of p70S6K and 4E-BP1 phosphorylation was observed at concentrations higher than or equal to 100 nM. We chose to restrict our study to the higher BEZ235 concentrations (250 nM and 1000 nM), 1000 nM being the only concentration that allowed a drastic inhibition of the phosphorylation of all the considered direct or indirect targets of PI3K, mTORC1 and mTORC2.
BEZ235 inhibits proliferation of SKOV3 and IGROV1-R10 cell lines without inducing apoptosis
We then explored the effect of BEZ235 on proliferation and induction of apoptosis in SKOV3 and IGROV1-R10 cell lines. 250 nM and 1000 nM of BEZ235 exerted a strong and persistent cytostatic effect in both cell lines ( Fig. 2A) . The analysis of DNA content histograms revealed that a 24 h-exposure to BEZ235 elicited a massive blockade of both cell lines in the G0/G1 phases; 81% of events for SKOV3 cells treated with 1000 nM BEZ235 versus 63% with DMSO control (Fig. 2B , left panel), and 76% of events for IGROV1-R10 cells treated with 1000 nM BEZ235 versus 54% with DMSO ( Fig. 2B , right panel). However, 250 nM and 1000 nM BEZ235 did not induce apoptosis in either cell line, as suggested by the absence of cell detachment, sub-G1 fraction on DNA histograms, nuclear condensation and fragmentation (Fig. 2B ) and of PARP and caspase 3 cleavages, even after 72 h (Fig. 2C) .
BEZ235 modulates the expression of Mcl-1 and its pro-apoptotic partners in SKOV3 and IGROV1-R10 cell lines
We then studied the expression of Mcl-1, Bcl-x L and Bcl-2 antiapoptotic proteins and that of the BH3-only proteins Bim, Puma and Noxa in response to a 24 h treatment with BEZ235. Compared to control, Mcl-1 protein expression reduced by around 50% in response to 250 nM and 1000 nM BEZ235 in both SKOV3 and IGROV1-R10 cell lines (Fig. 3A and B) . BEZ235 treatment affected neither Bcl-x L nor Bcl-2 expression levels (Bcl-2 is not expressed in IGROV1-R10, Fig. 3A) . Interestingly, BEZ235 induced a dosedependent increase in Bim protein expression in IGROV1-R10 cells (2.2-fold increase in response to 1000 nM BEZ235 as compared to control, Fig. 3A and B) . In SKOV3 cells, the level of Bim protein was very low and remained unchanged in response to treatment. However, BEZ235 triggered an upregulation of Bim mRNA in both cell lines (1.8-fold increase in response to 1000 nM BEZ235 as compared to control in SKOV3 cells and a 2.3-fold increase in response to 1000 nM BEZ235 as compared to control in IGROV1-R10 cells, Fig. 3C ), although the basal Bim mRNA level was approximately 3-fold lower in the SKOV3 cell line as compared to the IGROV1-R10 cell line. Concerning Puma protein expression, it was dosedependently upregulated by BEZ235 treatment in both cell lines, the upregulation being even stronger in the SKOV3 cell line (11.3-fold increase in response to 1000 nM BEZ235 as compared to control, Fig. 3A ) than in the IGROV1-R10 cell line (2.2-fold increase in response to 1000 nM BEZ235 as compared to control, Fig. 3A) . Finally, the expression of Noxa appeared to be on the contrary downregulated in response to treatment (Fig. 3A) .
Combining BEZ235 with inhibition of Bcl-x L expression or activity induces massive cell death in the IGROV1-R10 cell line
We first evaluated the impact of combining BEZ235 treatment with the siRNA-induced inhibition of Bcl-x L expression. IGROV1-R10 cells were transfected with Bcl-x L siRNA and treated 48 h later with BEZ235 for 24 h. This protocol was designed to ensure that optimal siRNA-mediated inhibition of Bcl-x L (observed 72 h after transfection, Fig. 4A ) coincided with optimal BEZ235-induced inhibition of Mcl-1 and upregulation of Bim and Puma. Coupling BEZ235 1000 nM with Bcl-x L siRNA triggered a massive apoptosis as shown by the strong cell detachment, the emergence of a sub-G1 peak on DNA histograms (60% of events), the observation of condensed and fragmented nuclei (Fig. 4B ) and the cleavage of both PARP and caspase 3 (Fig. 4C) . On the contrary, combining BEZ235 with control siRNA was not cytotoxic (Fig. 4B and C) . Real-time cell analysis (xCELLigence RTCA technology) also confirmed the cytotoxic effect of the siBcl-x L /BEZ235 combination (Fig. 4D) . Indeed, a dramatic drop in the cell index occurred following transfection of the cells with siBcl-x L and their treatment with BEZ235. This was in contrast to the growth stagnation elicited by siBcl-x L transfection alone or the only slight decrease in cell index observed following transfection of siCtrl combined with BEZ235 treatment.
We next associated BEZ235 treatment with inhibition of Bcl-x L activity using the BH3-mimetic molecule ABT-737 in the IGROV1-R10 cell line. As the modulation of Mcl-1, Bim and Puma protein expression by BEZ235 is supposed to occur more slowly than the inhibition of Bcl-x L activity by ABT-737, ABT-737 (5 lM) was added 24 h after BEZ235 treatment, when both the inhibition of Mcl-1 and the upregulation of Bim and Puma were optimal.
Analysis was performed 24 h later. Alone, ABT-737 elicited no significant apoptosis (Fig. 4E ) but when combined with BEZ235, it induced massive cell death as demonstrated by the presence of cell detachment, a sub-G1 fraction on DNA histograms (56% of events, Fig. 4E , left panel) and the detection of PARP and caspase 3 cleaved forms (Fig. 4E, right panel) .
We next investigated whether the BEZ235-induced upregulations of Bim and Puma were involved in the apoptotic cell death in response to the BEZ235/ABT-737 combination. We silenced Bim or Puma expression before exposing cells to the combination treatment and studied the apoptotic response of cells (Fig. 4F) . Our results showed that silencing Puma did not induce any resistance to the BEZ235/ABT-737 combined treatment, precluding that the BEZ235-induced upregulation of Puma could be involved in the observed cell death (Fig. 4F) . In contrast, cells transfected with Bim siRNA displayed a lower level of apoptosis than cells transfected with control siRNA in response to the combined treatment, highlighting a role of Bim in BEZ235/ABT-737-mediated cell death (Fig. 4F) . Immunoprecipitation studies revealed that in BEZ235-treated cells, overexpressed Bim was strongly trapped and hence perhaps had its pro-apoptotic role impeded by Bcl-x L (Fig. 4G ). This 
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BEZ235 (nM) Fig. 1 . BEZ235 inhibits PI3K/Akt/mTOR pathway activation in platinum-resistant SKOV3 and IGROV1-R10 ovarian cancer cell lines. Analysis of PI3K/Akt/mTOR pathway activation was performed by studying protein expression of P-Akt (Ser 473 and Thr 308) and total Akt, P-p70S6K (Thr389) and total p70S6K, and P-4E-BP1 (Thr70) and total 4E-BP1 by western-blot in SKOV3 and IGROV1-R10 cell lines, at basal state (A) or after a 24 h treatment with increasing concentrations of BEZ235 (B). Expression of b-actin was measured as a loading control. The western-blots shown are from one experiment representative of at least three independent experiments and cell lysates.
could explain why Bcl-x L -targeting strategies are efficient in this context and may suggest again a role of Bim in BEZ235/ABT-737-mediated apoptosis.
We then evaluated the impact of the BEZ235/ABT-737 combination in the platinum-sensitive IGROV1 cell line from which the IGROV1-R10 cell line was established. We first verified that BEZ235 (1000 nM) efficiently inhibited PI3K/Akt/mTOR pathway activation ( Supplementary Fig. 1A ), repressed Mcl-1 expression and induced Bim expression ( Supplementary Fig. 1B ) in this cell line. Moreover, we showed that the effect triggered by the BEZ235/ABT-737 combination in IGROV1 cells was quite similar to the one observed in IGROV1-R10 cells ( Supplementary Fig. 1C  and D) .
Finally, to exclude that the results obtained with the BEZ235/ ABT-737 combination in IGROV1-R10 cells could be ascribed to off target effects of BEZ235, we studied the impact of combining another PI3K/mTOR dual inhibitor, BGT226, with ABT-737. An 8 h treatment with 250 nM BGT226 alone drastically inhibited PI3K/ Akt/mTOR pathway activation (Supplementary Fig. 2A 
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Combining BEZ235 with CI-1040-induced Bim expression sensitizes the SKOV3 cell line to ABT-737
We next investigated the combination of BEZ235 with either Bcl-x L siRNA transfection (Fig. 5A) or ABT-737 (Fig. 5B ) in the SKOV3 cell line and showed that neither of these strategies was effective. As described above, BEZ235 treatment repressed Mcl-1 protein expression and induced Puma protein expression but it did not promote Bim protein expression in the SKOV3 cell line, in contrast to that observed in the IGROV1-R10 cell line (Fig. 3A  and B) . Based on these findings, we hypothesized that the inefficacy of the combined treatment in SKOV3 cell line could be ascribed to failure of BEZ235 to induce Bim. As Bim can be phosphorylated by ERK1/2 on serine 69, resulting in its proteasomal degradation [41] , we investigated the level of ERK1/2 phosphorylation (Thr202/Tyr204) in SKOV3 cells as compared to IGROV1-R10 cells. ERK1/2 activation was 3-fold stronger in the SKOV3 cell line than in the IGROV1-R10 cell line (Fig. 5C , upper panel). Moreover, the high level of ERK1/2 phosphorylation was not modified in response to BEZ235 treatment in SKOV3 cells (Fig. 5C, lower panel) . These results could explain the low level of Bim expression observed in SKOV3 cell line both at the basal level and in response to BEZ235. The treatment of SKOV3 cells with CI-1040 MEK inhibitor, which drastically abrogated ERK1/2 phosphorylation, efficiently upregulated the expression of Bim (Fig. 5C, lower panel) . Moreover, this protein appeared in its dephosphorylated form, as demonstrated by the shift of the corresponding band (Fig. 5C, lower panel) . This CI-1040-induced Bim expression was further increased by BEZ235 (Fig. 5C, lower panel) . Otherwise, CI-1040 modified Puma expression neither at basal state nor in response to BEZ235 (Fig. 5C, lower panel) . We then studied whether restoration of Bim expression in the SKOV3 cell line could confer sensitivity to ABT-737/BEZ235 treatment. Indeed, CI-1040 coupled with BEZ235 sensitized the SKOV3 cell line to ABT-737 (Fig. 5D) ; while BEZ235/CI-1040 treatment alone did not display any toxicity, its combination with ABT-737 induced a massive apoptosis in the SKOV3 cell line, as demonstrated by morphological features of the cell layers, sub-G1 peak (52% of events, Fig. 5D , left panel) and PARP and caspase 3 cleavages (Fig. 5D, right  panel) . Similar results were obtained when BEZ235 was replaced by BGT226 ( Supplementary Fig. 3A-D) . Interestingly, transfection of SKOV3 cells with Bim siRNA partially protected SKOV3 cells against BEZ235/CI-1040/ABT-737-induced apoptosis, suggesting that the observed effect of ERK inhibition on the apoptotic response to BEZ235/ABT-737 was dependent on Bim (Fig. 5E) . Moreover, silencing Puma also induced some resistance to the combined treatment, implying that Puma upregulated by BEZ235 was involved in the observed apoptosis. Finally, the inhibition of both Bim and Puma expressions strengthened the resistance observed when Bim or Puma were inhibited separately (Fig. 5E ).
Discussion
The poor outcome of patients diagnosed with ovarian carcinoma and treated with conventional chemotherapy emphasizes the urgent need to develop innovative therapies. In a previous study, we demonstrated that targeting both Bcl-x L and Mcl-1 by a siRNA approach efficiently eradicated ovarian carcinoma cells [4] . The objective of the present work was to assess the efficacy of a strategy combining Bcl-x L inhibition by the BH3-mimetic molecule ABT-737 and Mcl-1 inhibition by pharmacological disruption of the PI3K/Akt/mTOR pathway upstream using BEZ235 in platinum-refractory cancer cell lines.
We have firstly confirmed that BEZ235 efficiently inhibits PI3K, mTORC1 and mTORC2 activity in our preclinical models of ovarian cancer. Indeed, it triggered dephosphorylation of mTORC1 targets 4E-BP1 and p70S6K and dephosphorylation of Akt both on the site targeted by mTORC2 (Ser473) and on the site targeted by PDK1 following PI3K activation (Thr308). Moreover, BEZ235 inhibited cell proliferation by eliciting a blockade in G0/G1 phases of IGROV1-R10 and SKOV3 cell lines. This underlines the dependency of ovarian cancer cell proliferation on the PI3K/Akt/mTOR pathway and confirms data in the literature showing that BEZ235 represses proliferation in ovarian cancer cells [37, 38] , as well as in other cancer cell types [32] [33] [34] [35] [36] .
Our results also highlight for the first time that BEZ235 decreases Mcl-1 protein expression in ovarian cancer cells. Dual inhibition of PI3K and mTOR by BEZ235 has been described to downregulate Mcl-1 expression in other tumour cell types such as myeloid leukaemia cells [29] , various lymphoma cells [36, 42] and EGFR-mutant lung cancer cells [43] . Mcl-1 can be in particular antagonized by the BH3-only proteins Bim and Puma. Our study first pointed out that BEZ235 upregulated Puma expression in ovarian cancer cell lines, as reported in other cell types [36, 42, 44] . In contrast to Mcl-1 and Puma, Bim protein was consistently differentially modulated by BEZ235 in the SKOV3 and IGROV1-R10 cell lines. In IGROV1-R10 cells, the dual inhibitor upregulated the expression of Bim protein, as described in other cell types [36, 45] , and also the expression of Bim mRNA. However, in SKOV3 cells, the basal protein expression level of Bim appeared very low and was not increased by BEZ235, as has previously been reported in HER2-amplified breast and EGFR-mutant lung cancer cell lines [43, 44] , despite an increase in the level of Bim mRNA. We therefore hypothesized that the low basal expression of Bim protein found in the SKOV3 cell line could result from a high rate of protein degradation. Bim can be phosphorylated by ERK1/2, which primes it for ubiquitination and proteasomal degradation [41] . In agreement with this, low protein levels of Bim correlated with high levels of P-ERK1/2 in SKOV3 cells, both in the basal state and in response to BEZ235. As a comparison, the basal P-ERK/ERK ratio in SKOV3 cells was 3-fold higher than that observed in IGROV1-R10 cells, which expressed high levels of Bim. Our results corroborate with those of a previous study showing that the SKOV3 cell line displays a high level of ERK activation associated with very high expression levels of EGFR and HER2 proteins upstream [46] . Finally, disrupting ERK1/2 phosphorylation using the CI-1040 MEK inhibitor allowed the induction of Bim protein in a dephosphorylated form, providing further evidence to implicate P-ERK1/ 2 in the low Bim protein expression in the SKOV3 cell line.
In the IGROV1-R10 cell line, treatment with BEZ235 did not elicit apoptosis, in spite of Mcl-1 downregulation and Bim and Puma upregulations. Bcl-x L anti-apoptotic protein, the expression of which remained high in response to BEZ235 treatment, could be responsible for this cell survival. Indeed, previous results of our team highlighted that concomitant inhibition of Bcl-x L and Mcl-1 was necessary to eradicate resistant ovarian carcinoma cells [4] [5] [6] . Moreover, our present findings show that Bcl-x L trapped BEZ235-induced upregulated Bim, thereby precluding its activity either as an inhibitor of residual Mcl-1 or as an activator of multidomain pro-apoptotic proteins. Interestingly and as hypothesized, our results demonstrate that combining Bcl-x L inhibiting strategies with BEZ235-induced inhibition of Mcl-1 expression efficiently eradicated IGROV1-R10 cells. Similar results were obtained using another PI3K/mTOR dual inhibitor, BGT226, which further validated our findings. The apoptotic cell death in response to BEZ235/ABT-737 treatment was partly dependent on BEZ235-induced Bim upregulation as silencing of Bim rendered cells partially 
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Events Sub-G1 52% DMSO ABT-737 5µM resistant to apoptosis in response to the combined treatment. On the contrary, BEZ235-induced Puma upregulation did not seem to play a role in the observed cell death. The strategy of combining BEZ235 and ABT-737 (or ABT-263) has also recently proved to be efficient against haematological cancer cells and, as suggested by our results, the Bim/Mcl-1 ratio appeared as a major determinant of the response to the combined treatment. Indeed, in myeloid leukaemia cells, the BEZ235-induced Mcl-1 downregulation was shown to contribute towards the BEZ235/ABT-737 lethality in a Bim-dependent manner [29] . In lymphoma cells, BEZ235 increased Bim and Puma expression in all studied cell lines, whereas BEZ235-mediated Mcl-1 downregulation was cell line dependent. Coupling BEZ235 with ABT-263 had a significant combinative effect only in the cell lines in which BEZ235 succeeded in downregulating Mcl-1 expression [36] . Elsewhere, in ovarian cancer cells cultured as 3D spheroids in reconstituted basement membrane, BEZ235/ABT-737 treatment induced spheroid disintegration [47] . In this study, the ABT-737 was used to bypass matrix-associated resistance mediated by BEZ235-induced Bcl-2 upregulation, however Mcl-1 expression and its role in the response to BEZ235 was not investigated. However, in SKOV3 cells that expressed very low levels of Bim (both at basal state and in response to BEZ235), BEZ235 did not efficiently sensitize cells to Bcl-x L -targeting strategies, although it did downregulate Mcl-1 expression and upregulate Puma expression. We postulated that inefficacy of this strategy could be ascribed to a low Bim expression level. We therefore used the MEK inhibitor CI-1040 to restore Bim expression and so attempted to trigger apoptosis with the BEZ235/ABT-737 combined treatment. The BEZ235/CI-1040/ABT-737 triple combination was indeed very efficient to eradicate SKOV3 cells. To our knowledge, only one study has explored the anticancer potential of a similar strategy, combining Navitoclax with both a PI3K and a MEK inhibitor in non-small cell lung cancer cell lines and pancreatic ductal adenocarcinoma derived cell lines [48] . Moreover, our results emphasize that CI-1040-induced Bim is involved in the apoptosis of SKOV3 cells, again underlining the role of Bim in the apoptosis occurring in response to the BEZ235/ABT-737 combination. Interestingly, BEZ235-induced Puma upregulation also contributes to the apoptosis in response to the BEZ235/CI-1040/ABT-737 combination, in contrast to what was described in IGROV1-R10 cells in response to the BEZ235/ABT-737 combination. It can be assumed that in the SKOV3 cell line that displays a very low level of Bim, the role of Puma is strengthened. In tyrosine kinase inhibitor-resistant lung and breast cancer cell lines that expressed low levels of Bim, it was reported that BEZ235-induced Puma expression was sufficient to sensitize to ABT-737 treatment [44] . In SKOV3 cells, Bim and Puma appeared to cooperate to induce cell death in response to BEZ235/ CI-1040/ABT-737 treatment as inhibiting both Bim and Puma induced a stronger resistance than silencing each of these proteins separately. Otherwise, apart from BEZ235/CI-1040/ABT-737 combination, none of the tested double combinations were efficient to eradicate SKOV3 cells. Our results thus demonstrated that coupling CI-1040 with ABT-737 was not cytotoxic in the SKOV3 cell line, contrarily to that reported in B-Raf and K-Ras mutant carcinoma cells [49] [50] [51] and in acute myeloid leukaemia cells [19] . Elsewhere, ERK1/2-mediated phosphorylation of Bim has been shown to promote its rapid dissociation from Mcl-1 and Bcl-x L [52] . It is conceivable therefore that in the SKOV3 cell line, CI-1040-mediated dephosphorylation of Bim should result in Bim binding to Mcl-1 and Bcl-x L . ABT-737 may disrupt Bcl-x L binding to Bim but the released Bim may be insufficient to efficiently inhibit Mcl-1 and/or to activate pro-apoptotic multidomain proteins Bax and Bak. Our results obtained in the SKOV3 cell line in response to BEZ235/ABT-737 and CI-1040/ABT-737 combinations altogether indicate the importance of considering the ratio between Mcl-1 and its BH3-only partners rather than the expression of each of them alone when elaborating ABT-737-sensitizing strategies. Our data finally show that concomitant inhibition of PI3K/Akt/mTOR and MEK/ERK pathways does not elicit apoptosis in SKOV3 cells, contrarily to findings in other cellular models [43, 53] . Thus, downregulation of Mcl-1 (promoted by BEZ235) and upregulation of Bim and Puma (promoted by CI-1040 and BEZ235 respectively) were not sufficient to break the antiapoptotic/proapoptotic rheostat and to commit cells to apoptosis in this model, likely due to Bim and Puma trapping by Bcl-x L .
To conclude, whereas BEZ235 did not exert a cytotoxic effect on its own, it interestingly modulated the expression of Bcl-2 family proteins. In particular, BEZ235 induced a strong increase in the Bim/Mcl-1 ratio that makes it an attractive sensitizer to BH3-mimetic molecules such as ABT-737 or ABT-263. Our study has thus highlighted for the first time that combining Bcl-x L -inhibiting strategies with BEZ235-induced inhibition of Mcl-1 expression is a powerful strategy to eradicate ovarian cancer cell lines, provided that Bim is highly expressed in response to BEZ235. We have also provided several arguments favouring the role of Bim in BEZ235/ ABT-737-induced cell death in our models. First, BEZ235/ABT-737 selectively elicited apoptosis in the IGROV1-R10 cell line in which Bim was upregulated by BEZ235, and not in the SKOV3 cell line in which Bim expression remained very low. Secondly, the MEK inhibitor CI-1040 upregulated Bim expression in SKOV3 cells and sensitized them to BEZ235/ABT-737-mediated lethality. Finally, silencing Bim expression elicited some resistance to BEZ235/ABT-737 treatment in IGROV1-R10 cells and to BEZ235/CI-1040/ABT-737 treatment in SKOV3 cells. Otherwise, our study has pointed out that in the SKOV3 cell line that displays a low level of Bim expression, BEZ235-induced Puma is also involved in the apoptosis triggered by the combined treatment. The concept of co-chemosensitization between BEZ235 and ABT-737 supported by our results is particularly attractive considering the potential clinical use of these two innovative molecules in chemoresistant ovarian carcinomas. Moreover, this work allows us to propose pharmacological inhibition of the ERK1/2 pathway as an original approach to sensitize low Bim-expressing tumours to the BEZ235/ABT-737 combination. These concepts are in keeping with mounting evidence in favour of the requirement for multi-targeting strategies to efficiently disrupt cancer cell survival networks.
